American medical technology innovator Breath Diagnostics was recently selected to give the opening presentation at a prominent event in California.
The company led this year’s Respiratory Innovation Summit (RIS) — an opening segment of the American Thoracic Society’s International Conference, held between May 16 to 17. This convention is one of the top international events centred around respiratory health, bringing together thousands of experts.
Breath Diagnostics was chosen from a highly competitive group of applicants to deliver a lecture about its innovative lung cancer screening technology. Only a select number of others were invited to give presentations at the San Francisco showcase.
Chief Executive Officer Ivan Lo and President Aaron Roebuck gave a speech and presented a poster about their OneBreath diagnostics system.
“Being chosen to kick off RIS 2025 is a testament to the innovative spirit and rigorous science driving Breath Diagnostics,” Roebuck said.
Poster: Breath Diagnostics
Read more: Breath Diagnostics now offering a compelling investment opportunity
Quick, easy, accurate, radiation-free
Breath Diagnostics was pleased to have the opportunity to engage with other industry leaders at the city’s Marriott Marquis hotel and forward its mission of saving lives through timely diagnosis. Its breath testing system could alleviate many of the headaches and health risks associated with low-dose CT scans in the years to come.
The convenient nature of the device could also boost the current low rate of screening uptake. Many people are unwilling to take the time to receive a low-dose computed tomography scan, viewing it as too time consuming.
“This platform allows us to showcase OneBreath, our patented, non-invasive breath analysis system, which is revolutionizing early lung cancer detection with its simplicity, accuracy, and accessibility,” Lo said.
There is a multi-billion-dollar opportunity for technologies like these. In the United States alone, the addressable market for lung cancer screening tech is worth an estimated US$63 billion.
“We were honoured to be selected to present and open the 2025 Respiratory Innovation Summit,” Lo added.
Roebuck speaks about OneBreath’s clinical validation and proven accuracy in San Francisco. Photo credit: Breath Diagnostics
Read more: Breath Diagnostics gives the public the chance to join the fight against cancer
Breath Diagnostics promotes its mission throughout the Golden State
The respiratory screening tech developer recently educated a crowd about OneBreath in another California City — Dana Point.
At the Life Science Intelligence (LSI) USA Emerging Medtech Summit, Lo enlightened attendees about the dire need for more efficacious screening technologies.
He also discussed how OneBreath works, talked about prominent organizations that have contributed funding to Breath Diagnostics (like the Bill & Melinda Gates Foundation), touched on issues with other breath testing systems and highlighted what makes his company’s technology superior.
Breath Diagnostics has the clinical data to back up that superiority claim.
“Requiring less than a minute of the patient’s time, this potentially life-saving technology has shown promise in studies involving lung cancer detection in over 800 patients across multiple clinical sites,” conference organizer LSI said in a blog post earlier this year.
Breath Diagnostics closed a US$1-million-dollar convertible note financing last fall.
More recently, the company launched a US$3-million-dollar Regulation CF (crowdfunding) offering for investors. Those interested in becoming shareholders now have that opportunity.
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
